CCND2 Recombinant Rabbit mAb (S-5473)

CCND2 (Cyclin D2) is a key member of the D-type cyclin family, which plays a central role in the initiation and progression of cell proliferation by primarily binding to and activating cyclin-dependent kinases CDK4 and CDK6, thereby driving the cell cycle transition from G1 to S phase. Its expression is tightly regulated by extracellular mitogenic signals, exhibiting specific spatiotemporal distribution in various tissues such as ovary, skeletal muscle, and B lymphocytes, and is indispensable for the formation of certain organs during embryonic development—for instance, CCND2-knockout mice display defects in cerebellar and retinal development. As a core component of the cell cycle engine, dysregulation of CCND2 is closely associated with various diseases: gene amplification or overexpression is commonly observed in malignant tumors such as breast cancer, colorectal cancer, and melanoma, promoting uncontrolled tumor cell proliferation. Recent studies have also identified germline activating mutations in the CCND2 gene as the causative factor for MPPH syndrome (megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome), a rare neurodevelopmental disorder characterized by cerebral cortical malformations and overgrowth. Therefore, CCND2 has garnered significant attention not only as a key biomarker for predicting the efficacy of CDK4/6 inhibitors in cancer therapy, but also as an important bridge for understanding both normal development and pathological processes through its regulatory mechanisms.